# A Study of Safety and Immunogenicity of a Malaria Vaccine Candidate

> **NCT00284973** · PHASE1 · COMPLETED · sponsor: **Shanghai Wanxing Bio-Pharmaceutical Co. Ltd.** · enrollment: 70 (—)

## Conditions studied

- Prophylaxis Against Plasmodium Falciparum Malaria

## Interventions

- **BIOLOGICAL:** Plasmodium falciparum Chimeric Prot. 2.9 - Montanide ISA 720

## Key facts

- **NCT ID:** NCT00284973
- **Lead sponsor:** Shanghai Wanxing Bio-Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 70 (—)
- **Last updated:** 2015-04-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00284973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00284973, "A Study of Safety and Immunogenicity of a Malaria Vaccine Candidate". Retrieved via AI Analytics 2026-09-17 from https://api.ai-analytics.org/clinical/NCT00284973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*